Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy.
Jakub BenkoMatej SamošTomáš BolekDana PrídavkováJakub JuricaMartin Jozef PéčPeter GalajdaMarián MokáňPublished in: Journal of diabetes research (2022)
Diabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetics is alarming. Moreover, outcomes in HFpEF are poor and could be compared to those of heart failure with reduced ejection fraction (HFrEF), with 1-year mortality ranging between 10 and 30%. In contrast to HFrEF, there is very limited evidence for pharmacologic therapy in symptomatic patients with preserved ejection fraction, and therefore, the optimal selection of treatment for diabetic HFpEF remains challenging. This narrative review article summarizes the currently available data on the pharmacological treatment of HFpEF in patients with diabetes.
Keyphrases
- ejection fraction
- heart failure
- aortic stenosis
- left ventricular
- type diabetes
- cardiac resynchronization therapy
- acute heart failure
- risk factors
- glycemic control
- wound healing
- stem cells
- magnetic resonance
- transcatheter aortic valve replacement
- aortic valve
- mitral valve
- metabolic syndrome
- electronic health record
- magnetic resonance imaging
- smoking cessation
- mesenchymal stem cells
- skeletal muscle
- adipose tissue
- big data
- drug induced
- cell therapy